Exicure to Present at Upcoming Investor Conferences

CHICAGO & CAMBRIDGE, Mass.–(BUSINESS WIRE)–#DigitalDrugDesign–Exicure, Inc. (Nasdaq: XCUR), a pioneer in gene regulatory and immunotherapeutic drugs utilizing spherical nucleic acid (SNA™) constructs, today announced presentations at the following investor conferences during the months of September and early October:

• H.C. Wainwright 21^st Annual Global Investment Conference
  
  Corporate update
  
  Presented by: CEO David Giljohann
  
  Monday, September 9, 2019 at 10:25am ET
  
  Location: New York, NY

• Ladenburg Thalmann 2019 Healthcare Conference
  
  Corporate update
  
  Presented by: CEO David Giljohann
  
  Tuesday, September 24, 2019 at 1:30pm ET
  
  Location: New York, NY

• Chardan’s 3rd Annual Genetic Medicines Conference
  
  Corporate update
  
  Presented by: Dr. David Giljohann
  
  Monday, October 7, 2019 at 2:00pm ET
  
  Location: New York, NY

  The Next Big Thing in Genetic Medicines
  
  Panelist: Dr. David Giljohann
  
  Tuesday, October 8, 2019 at 9:30am ET
  
  Location: New York, NY

An audio webcast will be available on the Investors section of Exicure’s website: www.exicuretx.com. The webcast will be archived for approximately 30 days following the event.

About Exicure, Inc.

Exicure, Inc. is a clinical-stage biotechnology company developing therapeutics for immuno-oncology, inflammatory diseases and genetic disorders based on our proprietary Spherical Nucleic Acid, or SNA technology. Exicure believes that its proprietary SNA architecture has distinct chemical and biological properties that may provide advantages over other nucleic acid therapeutics and may have therapeutic potential to target diseases not typically addressed with other nucleic acid therapeutics. Exicure’s lead program is in a Phase 1b/2 trial in patients with advanced solid tumors. Exicure is based outside of Chicago, IL and in Cambridge, MA. www.exicuretx.com

Contacts

MacDougall

Karen Sharma

781-235-3060

[email protected]